Enterome's OncoMimics peptide-based immunotherapy EO2401 generates and maintains elevated anti-tumor T cell responses for more than 10 months in patients with recurrent glioblastoma

Memory CD8+ T cell response found as early as two weeks after the first administration of EO2401, expanding to up to 5% of circulating specific CD8+ T cells in some patients Immunological

Related Keywords

Boston ,Massachusetts ,United States ,Paris ,France General ,France ,Guillaume Bayre ,Kostenloser Wertpapierhandel ,Prnewswire Enterome ,Sylvie Berrebi Mark ,Jan Fagerberg ,Head Of External Communications ,Society For Immunotherapy Of Cancer ,Health Science ,Annual Meeting ,Chief Medical Officer ,Presentation Details ,Mark Swallow ,Enterome ,Ncomimics ,Peptide ,Ased ,Immunotherapy ,O2401 ,Generates ,Aintains ,Levated ,Anti ,Humor ,Fell ,Responses ,More ,Han ,Months ,Patients ,Recurrent ,Glioblastoma ,